Alzheimer Disease Research Unit, Alzheimer Center Reina Sofía Foundation, CIEN Foundation, Carlos III Institute of Health, Madrid, Spain.
J Alzheimers Dis. 2013;36(2):297-302. doi: 10.3233/JAD-130077.
We conducted a pilot, randomized, controlled trial to mainly investigate the feasibility, safety, and short-term motor effects of brain stimulation with radio electric asymmetric conveyer (REAC) technology in patients with advanced Alzheimer's disease (AD) who also experience some gait dysfunction. Neuropostural optimization (NPO) or sham protocol was administered to 31 nursing home patients (mean [SD] age 84.7 [7.0], 77.4% female, 6.5% moderate dementia, 51.6% moderately severe dementia, and 41.9% severe dementia). Motor, cognitive, functional, and behavioral measures were conducted at baseline (T1), immediately after treatment (T2), and 1-3 weeks after treatment (T3). There was transitory dysfunction in axial movements at T2 in the experimental group with no other differences between the experimental group and the control group in the planned analyses. However, after reanalysis of data based on outcome, improvement in capacity of walking was observed at T3 in the experimental group (p < 0.05). NPO administration was comfortable and safe. These results warrant further research with NPO and other REAC protocols to improve motor deterioration in AD.
我们进行了一项初步的、随机的、对照试验,主要研究针对伴有一些步态功能障碍的晚期阿尔茨海默病(AD)患者,应用无线电电不对称传输(REAC)技术的脑刺激的可行性、安全性和短期运动效果。神经姿势优化(NPO)或假协议被应用于 31 名养老院患者(平均[标准差]年龄 84.7[7.0],77.4%为女性,6.5%为中度痴呆,51.6%为中度严重痴呆,41.9%为严重痴呆)。在基线(T1)、治疗后即刻(T2)和治疗后 1-3 周(T3)进行了运动、认知、功能和行为测量。在实验组 T2 时出现短暂的轴向运动功能障碍,但实验组与对照组在计划分析中无其他差异。然而,根据结果重新分析数据后,实验组在 T3 时观察到步行能力的改善(p<0.05)。NPO 给药舒适且安全。这些结果支持进一步研究 NPO 和其他 REAC 方案,以改善 AD 患者的运动恶化。